诚意药业(603811.SH)：盐酸多巴酚丁胺注射液通过仿制药一致性评价

Core Viewpoint - Chengyi Pharmaceutical (603811.SH) has received approval from the National Medical Products Administration for its supplementary application, confirming that its product, Dobutamine Hydrochloride Injection, has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved product, Dobutamine Hydrochloride Injection, is primarily used for heart failure caused by decreased myocardial contractility in organic heart disease, including low cardiac output syndrome following cardiac surgery, serving as a short-term supportive treatment [1]